Trial
NCT03517501
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Phase IIIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
Asahi Kasei Pharma America Corporation
Collaborators
—
Condition
Sepsis and Coagulopathy
Intervention
ART-123
Why stopped
Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-13